Incidence and outcome of high on-treatment platelet reactivity in patients with non-st elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [verifynow and inhibition of platelet reactivity] study)

American Journal of Cardiology

Volumn 112, Issue 6, 2013, Pages 792-798

  Saia, Francesco ^a   Marino, Massimiliano ^b   Campo, Gianluca ^c   Valgimigli, Marco ^c   Guastaroba, Paolo ^b   Taglieri, Nevio ^a   Tondi, Stefano ^d   Manari, Antonio ^e   Guiducci, Vincenzo ^e   Sangiorgio, Pietro ^f   Varani, Elisabetta ^g   Magnavacchi, Paolo ^d   De Palma, Rossana ^b   Marzocchi, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Regional Health Care Agency   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d Baggiovara Hospital   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RESIDUAL PLATELET REACTIVITY; SEX DIFFERENCE; STENT; TREATMENT OUTCOME; ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FOLLOW UP; ITALY; MULTICENTER STUDY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; AGED; CORONARY ANGIOGRAPHY; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; ITALY; MALE; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PROGNOSIS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STROKE; TICLOPIDINE;

EID: 84886702699     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.010     Document Type: Article

References (24)

1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
3. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.
4. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month followup. Circulation 2009;119:237-242.
5. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-1223.
6. PriceMJ,Angiolillo DJ, Teirstein PS, Lillie E,Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-1137.
7. Brar SS, ten Berg J,Marcucci R, Price MJ,Valgimigli M, KimHS, PattiG, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-1954.
8. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57: 2474-2483.
9. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (Registro Angioplastiche dell'Emilia Romagna) multicenter registry. Circulation 2007;115:3181-3188.
10. Saia F, Piovaccari G, Manari A, Guastaroba P, Vignali L, Varani E, Santarelli A, Benassi A, Liso A, Campo G, Tondi S, Tarantino F, De Palma R, Marzocchi A. Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry. Euro- Intervention 2009;5:57-66.
11. Saia F, Piovaccari G, Manari A, Santarelli A, Benassi A, Aurier E, Sangiorgio P, Tarantino F, Geraci G, Vecchi G, Guastaroba P, Grilli R, Marzocchi A. Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: results from a large multicenter registry. J Am Coll Cardiol 2006;48:1312-1318.
12. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drugeluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934.
13. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, WhiteHD, FoxKA, Prabhakaran D, ArmstrongPW, TantryUS, RoeMT. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012;308:1785-1794.
14. Sibbing D, Bernlochner I, Schulz S, Massberg S, Schomig A, Mehilli J, Kastrati A. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-STsegment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol 2012;60:369-377.
15. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S,RobbinsM,GarrattKN, BertrandOF, StillablowerME,Aragon JR, KandzariDE, Stinis CT, LeeMS,Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-1105.
16. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, CarrieD, Boueri Z, Belle L,Van Belle E, RousseauH,Aubry P, Monsegu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O, Beygui F, Silvain J, Vicaut E, Montalescot G. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.
17. SibbingD, Schulz S, Braun S,Morath T, Stegherr J,Mehilli J, SchomigA, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-256.
18. Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome-a systematic review. Heart 2013;99:520-527.
19. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509.
20. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719.
21. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF.ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619-2633.
22. Cuisset T, Quilici J, Loosveld M, Gaborit B, Grosdidier C, Fourcade L, Gil JM, Moro PJ, Morange PE, Bonnet JL, Alessi MC. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. Am Heart J 2012;164:327-333.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
24. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.